IMMUNEONCO BIOPHARMACEUTICALS (SHAN financial statements, including revenue, expenses, profit, and loss
The total revenue of 1541 for the last semiannual is 324.10 k HKD, and it's 233.23% higher compared to the previous semiannual. The net income of H2 23 is -225.39 M HKD.